Leukemia Clinical Trials
Phase I Agents for Hematologic Malignancies
- Sapacitabine (2009-1002)
- Hu8F4 (2014-0057)
- Bosutinib + Inotuzumab (2014-0435)
- APTO-253 (2014-0528)
- SL-401(2014-0976)
- AMG 330 (2015-0296)
- K0706 (2016-0648)
- SEL24 (2016-0713)
- Palbociclib (2016-0772)
- MGD006 (2017-0027)
- AZD5991 (2017-0702)
- AMG 176 (2017-0776)
- Hu5F9-G4 + AZA (2017-0795)
- IMGN632 (2017-0855)
- UCART22 (2017-1003)
- CK 0801 (2018-0010)
- Ph I CYC065+Venetoclax (2018-0316)
- DS-3032b + LD Ara-C (2018-0333)
- APG-2575 (2018-0527)
- AMG427 (2018-0596)
- Quizartinib + Venetoclax (2018-0608)
- GSK3326595 (2018-0634)
- Venetoclax + Gilteritinib (2018-0675)
- PLX51107 (2018-0725)
- CPX-351 (2018-0911)
- HM43239 (2018-0918)
- Itacitinib + Alemtuzumab (2019-0054)
- PRT543 (2019-0113)
- PTC299 (2019-0122)
- PBCAR0191 (2019-0218)
- CYC065 + Venetoclax (2019-0241)
- CPX-351 + Quizartinib (2019-0351)
- AZA + Venetoclax + Gilteritinib (2019-0366)
- Venetoclax + Aza (2019-0368)
- IMG632 + Venetoclax +/- AZA (2019-0656)
- HQP1351 (2019-0705)
- Voruciclib (2019-0738)
- APR-246 + Venetoclax +/- AZA (2019-0760)
- JNJ-63709178 (CD123-CD3) (2019-0911)
- KRT-232 + LDAC (2019-0914)
- JNJ-74494550 + AZA or Venetoclax or AZA + Venetoclax (2019-0989)
- SNDX-5613 (2019-0997)
- ASTX660 or ASTX660 + ASTX727 (2019-1080)
- LP-108 (2019-1089)
- TAS1440 or TAS1440 + ATRA (2019-1231)
- CC-90009 + Gilteritinib or CC-90009 + Venetoclax + AZA (2019-1233)
- CA-4948 (2019-1246)
- Oral AZA + ASTX030 vs. SQ AZA (2020-0025)
- AZA + Venetoclax + Magrolimab (2020-0027)
- Venetoclax + ASTX727 (2020-0129)
- Blinatumomab (2020-0133)
- VLS-101 (2020-0154)
- TC-110 (2020-0207)
- NKX101 (2020-0227)
- CB-5339 (2020-0302)
- INCB000928 +/- Ruxolitinib (2020-0409)
- APR-246 + Venetoclax (2020-0411)
- APG-115 + AZA (2020-0422)
- Fludarabine + Ara-C + Pegristantaspase (2020-0434)
- IO-202-CL-001 (2020-0492)
- SEA-CD70 (2020-0615)
- GFH009 (2020-0689)
- BP1002 (2020-0719)
- PRT1419 (2020-0740)
- APG-1252 + Ruxolitinib (2020-0814)
- TAS1553 (2020-0832)
- CG-806 (2020-0900)
- DS-1594 +/- AZA + Venetoclax or mini HCVD (2020-0946)
- BGB-11417 (2020-0956)
- ASTX727 + Venetoclax (2020-0965)
- CFI-400945 +/- AZA or Decitabine (2020-1061)
- ONO-7475 (2020-1082)
- Fostamatinib (2020-1117)
- NX-2127 (2020-1169)
- HMPL-306 (2020-1321)
- KITE-222 (2021-0007)
- AZD0466 (2021-0032)
- ASTX727 + Venetoclax + Gilteritinib (2021-0082)
- FHD-286 (2021-0121)
- JNJ-7526617 (2021-0319)
- FT538 (2021-0414)
Monoclonal
CD33
CD123
- SL-401(2014-0976)
- SL401 + AZA (2017-0354)
- XmAb 14045 (2016-0165)
- IMGN632 (2017-0855)
- MGD006 (2017-0027)
- IMG632 + Venetoclax +/-AZA (2019-0656)
- CPX-351 (2018-0911)
CD22
HLA
- HU8F4 (2014-0057)
FLT3
- AMG427 (2018-0596)
CD47
- Hu5f9-G4 + AZA (2017-0795)
IO-202
- IO-202 (2020-0492)
IDH Inhibitors
- HMPL-306 (2020-1321)
- AG120 (2017-0490)
- AG120 (2014-0800)
- CPX-351 + Ivosidenib (2020-0096)
- Enasidenib + AZA (2018-0499)
- LY3410738 (2020-0676)
- Ivosidenib or Enasidenib (2020-1220)
CAR-T Studies
B-ALL
- U-CART22 in R/R CD22+ B-ALL (2017-1003)
- PBCAR0191 (CAR-T) in R/R B-Cell ALL (2019-0218)
- TCR2 (2020-0207)
CLL
- JCAR017 in R/R CLL or SLL (Auto CART) (2017-0751)
- PBCAR0191 (CAR-T) in R/R B-Cell ALL (2019-0218)
- iC9/CAR (2016-0641)
AML
- U-CART123 in RR AML (2017-0559)
AML/MDS
- NKX101 (2020-0227)
Other Cellular AML
Menin Inhibitors
Acute Lymphoblastic Leukemia (ALL)
Newly Diagnosed or Previously Treated
- Hyper CVAD + Blinatumomab (2014-0845)
- mHCVD + Inotuzumab +/-Blinatumomab (2010-0991)
- Hyper-CVAD + Nelarabine (2006-0328)
- Low-Intensity Chemo + Venetoclax (2016-0629)
- Hyper-CVAD + Ponatinib (2011-0030)
- Ponatinib vs. Imatinib + Reduced Intensity Chemo (2018-0434)
- Blinatumomab + Ponatinib (2016-0792)
- Hyper CVD + Ponatinib (2016-0402)
- Bosutinib + Inotuzumab (2014-0435)
- EPOCH + Ofatumumab (2014-0123)
Minimal Residual Disease
Salvage Programs
- Blinatumomab (2020-0133)
- Low-Intensity Chemo + Venetoclax (2016-0629)
- Blinatumomab + AMG (2020-0135)
- AUTO1-AL1 (2020-0435)
- ADCT-602 (2017-0938)
- UCART22 (2017-1003)
- DS-1594 +/- AZA + VEN or mini HCVD (2020-0946)
- TC-110 (2020-0207)
- iC9/CAR (2016-0641)
- EPOCH + Ofatumumab (2014-0123)
- CEC + VCR + Bortezomib (2016-0211)
- Blinatumomab + Ponatinib (2016-0792)
- Bosutinib + Inotuzumab (2014-0435)
- Hyper CVD + Ponatinib (2016-0402)
- Ponatinib + Venetoclax (2017-0313)
- BL-8040 + Nelarabine (2016-1101)
- Hyper-CVAD + Nelarabine (2006-0328)
- Palbociclib (2016-0772)
- SNDX-5613 (2019-0997)
Phase I/II Open to ALL
Acute Myeloid Leukemia (AML)
Newly Diagnosed
- Fludarabine + Ara-C + G-CSF + Gemtuzumab (2007-0147)
- ATRA and arsenic +/- Gemtuzumab (2010-0981)
- Cladribine + Ida + Ara-C (2012-0648)
- FLAG-Ida + Venetoclax (2016-0979)
- CPX-351 + Venetoclax (2017-1055)
- CLIA + Quizartinib (2017-0153)
- Venetoclax + Daunorubicin/Ara-C (2019-0591)
- BP1001 + LD Ara-C (2016-0128)
- Dexrazoxane (2017-0937)
- Venetoclax + Cladribine + LDAC + LDAC w/ AZA (2018-0020)
- Cladribine + LD Ara-C alternating DAC (2011-0987)
- Venetoclax + ASTX727 (2020-1007)
- MBG453 + AZA + Venetoclax (2020-0030)
- Nivolumab + AZA (2014-0861)
- Venetoclax + Decitabine (2017-0912)
- Dexrazoxane (2017-0937)
- CART123 (2017-0559)
- SL401 + AZA (2017-0354)
- ALX148 + Venetoclax + AZA (2021-0144)
- AZA + Venetoclax + Magrolimab (2020-0027)
- JNJ-74494550 + AZA or Ven or AZA + Venetoclax (2019-0989)
- BGB324 (2014-0756)
- Pevonedistat + Ven + AZA vs Ven + AZA (2020-0301)
- ASTX727 + Venetoclax (2020-0965)
FLT3 Mutated Only
- CLIA + Quizartinib (2017-0153)
- AZA + Venetoclax + Gilteritinib (2019-0366)
- Quinzartinib + DAC (2018-0394)
- Quizaritinib + AZA (2019-1178)
- Quizartinib + LC Ara-C (2012-1047)
- CPX-351 + Quizartinib (2019-0351)
IDH Mutated only
- AG120 (2017-0490)
- CPX-351 + Ivosidenib (2020-0096)
- LY3410738 (2020-0676)
- Enasidenib + AZA (2018-0499)
- Ivosidenib or Enasidenib (2020-1220)
Frontline AML Post-Hypomethylating Therapy for MDS
- Uproleselan + Cladribine + Low-Dose Cytarabine (2020-0988)
- Venetoclax + ASTX727 (2020-1007)
- Nivolumab + AZA (2014-0861)
- BP1001 + LD Ara-C (2016-0128)
- Nivolumab + Ipilimumab with AZA (2014-0930)
Secondary Leukemia
- Uproleselan + Cladribine + Low-Dose Cytarabine (2020-0988)
- AZA + ABT-199 + Pevonedistat (2018-0724)
- Venetoclax + ASTX727 (2020-1007)
- Cladribine + LD Ara-C alternating DAC (2011-0987)
Mixed Phenotype Acute Leukemia
- SNDX-5613 (2019-0997)
- Clofarabine, Ida, Ara-C, VCR, and Corticosteroids (2013-0073)
- DS-1594 +/- AZA + Venetoclax or mini HCVD (2020-0946)
Salvage
FLT3 Positive at relapse
- CLIA + Quizartinib (2017-0153)
- ASTX727 + Venetoclax + Gilteritinib (2021-0082)
- Cladribine + Ida + Ara-C + Sorafenib (2012-0648)
- AZA + Ven + Gilteritinib (2019-0366)
- Quinzartinib + DAC (2018-0394)
- Quizartinib + Venetoclax (2018-0608)
- Venetoclax + Gilteritinib (2018-0675)
- HM43239 (2018-0918)
- Palbociclib (2016-0772)
- Venetoclax + Decitabine (2017-0912)
- Quizartinib + LC Ara-C (2012-1047)
- CPX-351 + Quizartinib (2019-0351)
- NKX101 (2020-0227)
RAS Mutated
AML with MLL gene at 11q23 Translocations
- SNDX-5613 (2019-0997)
- KO-539 (2020-0717)
- NKX101 (2020-0227)
- DS-1594 +/- AZA + Venetoclax or mini HCVD (2020-0946)
AML with mutation in NPM1
- SNDX-5613 (2019-0997)
- KO-539 (2020-0717)
- NKX101 (2020-0227)
- DS-1594 +/- AZA + Venetoclax or mini HCVD (2020-0946)
IDH Mutated
- HMPL-306 (2020-1321)
- LY3410738 (2020-0676)
- AG120 (2017-0490)
- Enasidenib + AZA (2018-0499)
- Venetoclax + Decitabine (2017-0912)
- NKX101 (2020-0227)
- Ivosidenib or Enasidenib (2020-1220)
All others (Regardless of mutation status)
- KO-539 (2020-0717)
- NKX101 (2020-0227)
- DS-1594 +/- AZA + Venetoclax or mini HCVD (2020-0946)
- Margrolimab (2021-0099)
- CPX-351 + Venetoclax (2017-1055)
- FLAG-Ida + Venetoclax (2016-0979)
- Pilot Study CPX-351 w/ Gemtuzumab (2018-0235)
- Venetoclax + ASTX727 (2020-1007)
- Cladribine + Ida + Ara-C + Sorafenib (2012-0648)
- Nivolumab + 5-AZA (2014-0861)
- Venetoclax + Decitabine (2017-0912)
- AMG 330 (2015-0296)
- CART123 (2017-0559)
- AMG673 (2017-0365)
- Daratumumab (2016-0889)
- SL401 + AZA (2017-0354)
- HiDAC + Mitoxantrone +/- CPI-613 (2019-0014)
- Fludarabine + Ara-C + Pegristantaspase (2020-0434)
- MGD006 (2017-0027)
- DS-3032b + LD Ara-C (2018-0333)
- BGB324 (2014-0756)
- Voruciclib (2019-0738)
- PTC299 (2019-0122)
- DFP-10917 vs Non-Intensive Reinduction (2019-0357)
- CA-4948 (2019-1246)
- BTX-A51 (2019-0511)
- GFH009 (2020-0689)
- CG-806 (2020-0900)
AML with Monocytic Differentiation
- IO-202 (2020-0492)
Maintenance (Patients in CR)
BPDCN Treatment Priorities
- SL-401 + HCVAD or mHCVAD + Venetoclax (2019-0587)
- IMGN632 (2017-0855)
- Venetoclax + Decitabine (2017-0912)
- Venetoclax + AZA (2018-0841)
- MB CAR-T (2019-0097)
- Post-SCT SL401 (2018-0646)
Myelodysplastic Syndrome (MDS) (Includes CMML)
Specific Situations
Hypoplastic MDS and aplastic anemia
- Horse ATG (2012-0334)
Splicing Mutations
- GSK3326595 (2018-0634)
MDS/MPN
FLT3 Positive
IDH Mutations
- CPX-351 + Ivosidenib (2020-0096)
Low Risk/IPSS Int-1
- ASTX727-03 (2018-0919)
- Roxadustat (FG-4592)/Placebo (2017-0042)
- ACE-536 vs Epoetin (2018-0179)
- Hu5F9-G4 + AZA (2017-0795)
IPSS int-2 or high
- Venetoclax/Placebo + AZA (2020-0180)
- Magrolimab/Placebo + AZA (2020-0546)
- ALX148 + AZA (2020-0572)
- Venetoclax + ASTX727 (2020-0129)
- Venetoclax + AZA (2019-0368)
- Cladribine + LD Ara-C alt DAC (2011-0987)
- Cladribine + Ida + Ara-C + Sorafenib (2012-0648)
- FLAG-Ida + Venetoclax (2016-0979)
- Venetoclax + Decitabine (2017-0912)
Post Hypomethylating Agents
- Oral AZA + ASTX030 vs. SQ AZA (2020-0025)
- Fostamatinib (2020-1117)
- Canakinumab (2019-0339)
- SL-401(2014-0976)
- Roxadustat (FG-4592)/Placebo (2017-0042)
- FHD-286 (2021-0121)
- INCB000928 (2020-0983)
- AZA + Cedazuridine (ASTX030) vs. SQ AZA (2020-0025)
- CA-4948 (2019-1246)
- Venetoclax + AZA (2020-0128)
- CPX-351 (2018-0911)
- Ven + AZA (2019-0368)
- SEA-CD70 (2020-0615)
- PRT1419 (2020-0740)
- FLAG-Ida + Venetoclax (2016-0979)
- Venetoclax + Decitabine (2017-0912)
- Pilot Study CPX-351 w/ Gemtuzumab (2018-0235)
- APR-548 + AZA (2020-1119)
- Seclidemstat + AZA (2020-0487)
Chronic Lymphocytic Leukemia (CLL)
CLL Immunotherapy
Untreated - early stage
- Ibrutinib (2017-0039)
Untreated - all stages
- Atezolizumab (2015-1097)
- Acalabrutinib + Ven + Obinutuzumab (2019-0565)
- Zanubrutinib + Rituximab (2019-0012)
- Acalabrutinib + Obinutuzumab (2019-1141)
Consolidation and Minimal Residual Disase (MRD)
- ABT-199 + Ibrutinib (2016-0785)
Prior Therapy
- LOXO-305 (2018-0850)
- BGB-11417 (2020-0956)
- BP1002 (2020-0719)
- NX-2127 (2020-1169)
- Acalabrutinib + Ven + Obinutuzumab (2019-0565)
- APR-246 + Venetoclax (2020-0411)
- FT819 (2020-0775)
- JCAR017 (2017-0751)
- APG-2575 (Bcl-2-i) (2018-0527)
- XmAb®13676 (2016-0991)
Richter’s Transformation
- VLS-101 (2020-0154)
- Atezolizumab (2015-1097)
- LOXO-305 (2018-0850)
- EPOCH-R + Venetoclax (2016-0900)
- XmAb®13676 (2016-0991)
Other Studies
T-Cell Prolymphocytic Leukemia (T-PLL)
- Itacitinib + Alemtuzumab (2019-0054)
- Ibrutinib + Venetoclax (2019-1069)
- APG-115 +/- APG-2575 (2020-1155)
Chronic Myelogenous Leukemia (CML)
Chronic phase
Accelerated Phase
Blastic Phase
- Decitabine + Venetoclax + Ponatinib (2019-0610)
- Dexrazoxane (2017-0937)
- Bosutinib + Inotuzumab (2014-0435)
- K0706 (2016-0648)
Imatinib failures with T315l mutations (any stage)
- K0706 (2016-0648)
Minimal Residual Disease
Myeloproliferative Neoplasms (MPN)
- KRT-232 or TL-895 (2020-1335)
- Navitoclax + Ruxolitinib (2020-0743)
- Navitoclax (2017-0495)
- Ruxolitinib + AZA (2012-0737)
- KRT-232 + Ruxolitinib (2020-0279)
- PU-H71 (2019-0019)
- TL-895 (2020-0738)
- CPI-0610 (2018-0202)
- KRT-232 (2018-0906)
- APG-1252 + Ruxolitinib (2020-0814)
- PRT543 (2019-0113)
- SL-401 (2014-0976)
- CK0801 (2018-0010)
- Hu8F4 (2014-0057)
- Elotuzumab (2020-0522)
- INCB000928 +/- Ruxolitinib (2020-0409)
- Pacritinib (2017-0320)
- INCB054828 (2016-0635)
- Ropeginterferon alfa-2b (P1101) (2020-0108)
Hemophagocytic Lymphohistiocytosis Studies (HLH)
APTO-253
Ve
netoclax + Gilteritinib (2018-0675) (NCT03625505)
AMG427 (2018-0596) (NCT03541369)
Quizartinib + Venetoclax (2018-0608) (NCT03735875)
GSK3326595 (2018-0634) (NCT03614728)
MEDI7247 (2018-1019) (NCT03106428)
CK 0801 (2018-0010) (NCT03773393)
ABBV-621 (2018-0676) (NCT03082209)
CYC065 + Venetoclax (2019-0241) (NCT04017546)
UCART22 (2017-1003) (NCT04150497)
PTC299 (2019-0122) (NCT03761069)
Sapacitabine (2009-1002) (NCT01211457)
brequinar (2018-0556) (NCT03760666)
PTC299 (2019-0122) (NCT03761069)
Hu5F9-G4 + AZA (2017-0795) (NCT03248479)
CPX-351 (2018-0911) (NCT03896269)
PBCAR0191 (2019-0218) (NCT0
3666000)
Q
Pacritinib
Give Now
Your gift will help make a tremendous difference.
Research Areas
Find out about the four types of research taking place at MD Anderson.
Subscribe
Get the latest information on our cancer breakthroughs.